Re: A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: The cancer and osteoporosis research with alendronate and leuprolide (CORAL) study: Editorial comment

Samir S. Taneja

doi:10.1016/j.juro.2013.01.075

Re: A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: The cancer and osteoporosis research with alendronate and leuprolide (CORAL) study: Editorial comment

Samir S. Taneja

Biomedical Engineering

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Pages (from-to)	1714
Number of pages	1
Journal	Journal of Urology
Volume	189
Issue number	5
DOIs	https://doi.org/10.1016/j.juro.2013.01.075
State	Published - May 2013

ASJC Scopus subject areas

Urology

Access to Document

10.1016/j.juro.2013.01.075

Cite this

Taneja, S. S. (2013). Re: A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: The cancer and osteoporosis research with alendronate and leuprolide (CORAL) study: Editorial comment. Journal of Urology, 189(5), 1714. https://doi.org/10.1016/j.juro.2013.01.075

Re: A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: The cancer and osteoporosis research with alendronate and leuprolide (CORAL) study: Editorial comment. / Taneja, Samir S.
In: Journal of Urology, Vol. 189, No. 5, 05.2013, p. 1714.

Research output: Contribution to journal › Comment/debate › peer-review

Taneja, SS 2013, 'Re: A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: The cancer and osteoporosis research with alendronate and leuprolide (CORAL) study: Editorial comment', Journal of Urology, vol. 189, no. 5, pp. 1714. https://doi.org/10.1016/j.juro.2013.01.075

Taneja SS. Re: A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: The cancer and osteoporosis research with alendronate and leuprolide (CORAL) study: Editorial comment. Journal of Urology. 2013 May;189(5):1714. doi: 10.1016/j.juro.2013.01.075

Taneja, Samir S. / Re : A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: The cancer and osteoporosis research with alendronate and leuprolide (CORAL) study: Editorial comment. In: Journal of Urology. 2013 ; Vol. 189, No. 5. pp. 1714.

@article{ebe2ebfe7aa449ef82636494ffcb7011,

title = "Re: A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: The cancer and osteoporosis research with alendronate and leuprolide (CORAL) study: Editorial comment",

author = "Taneja, {Samir S.}",

year = "2013",

month = may,

doi = "10.1016/j.juro.2013.01.075",

language = "English (US)",

volume = "189",

pages = "1714",

journal = "Journal of Urology",

issn = "0022-5347",

publisher = "Elsevier Inc.",

number = "5",

}

TY - JOUR

T1 - Re

T2 - A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: The cancer and osteoporosis research with alendronate and leuprolide (CORAL) study: Editorial comment

AU - Taneja, Samir S.

PY - 2013/5

Y1 - 2013/5

UR - http://www.scopus.com/inward/record.url?scp=84876261947&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876261947&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2013.01.075

DO - 10.1016/j.juro.2013.01.075

M3 - Comment/debate

C2 - 23594627

AN - SCOPUS:84876261947

SN - 0022-5347

VL - 189

SP - 1714

JO - Journal of Urology

JF - Journal of Urology

IS - 5

ER -

Re: A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: The cancer and osteoporosis research with alendronate and leuprolide (CORAL) study: Editorial comment

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this